HANTECH BIO-TECH plans to list on the Taipei Exchange (TPEx) in late September. (Photo / Kuo Hung-Hui)
[China Times Info Reporter Kuo Hung-Hui / Taipei] HANTECH BIO-TECH (1294), advised by CTBC Securities, is a well-known Taiwanese contract manufacturer of liquid and crystal-jelly health supplements. The company specializes in a wide variety of retort pouch packaging formats and customized formulations. It is expected to officially list on the Taipei Exchange (TPEx) in late September and will hold its pre-listing investor conference tomorrow (Aug. 28).
Chairman Lee Yu-Lin said the company hopes to leverage its TPEx listing to gain advantages in access to capital, talent recruitment, and brand visibility, while securing more ODM orders and creating additional momentum for business growth.
HANTECH BIO-TECH previously focused primarily on the Taiwan market but has recently accelerated its overseas expansion. The company has already developed customers in China, Hong Kong, Malaysia, and Singapore. As well-known domestic and international health supplement brands continue to launch functional liquid beverages and expand these products into overseas markets, market demand continues to increase.
In addition to its existing Yuanlin plant, HANTECH’s Xihu Headquarters facility officially began operations this year. The expansion of new customers, new products, and new sales regions is expected to continue contributing to revenue growth.
HANTECH BIO-TECH is a leading contract manufacturer of liquid retort pouch health supplements. Currently, the majority of its contract manufacturing projects are ODM projects, in which ingredients are supplied by HANTECH, accounting for approximately 90% of total projects. OEM projects, in which ingredients are supplied by customers, account for approximately 10%.
HANTECH BIO-TECH noted that retort pouch packaging offers advantages such as lower transportation and packaging material costs. As major health supplement brands increasingly shift to this packaging format, the trend is expected to have a positive impact on the company’s operations.
HANTECH BIO-TECH was founded in 2007 and initially focused on the sale of traditional Chinese medicinal ingredients, particularly Guilu-related materials. In 2010, the company began developing low-temperature grinding technology for ultra-fine nano pearl powder. In 2012, it introduced horizontal filling machines and sterilization equipment for retort pouches and expanded into health supplement filling and contract manufacturing services.
Today, the company’s core businesses include the R&D, ODM, and OEM manufacturing of liquid and crystal-jelly health supplements. HANTECH provides comprehensive one-stop contract manufacturing services covering everything from formulation design to retort pouch filling and packaging, while also developing health supplement ingredients.
HANTECH BIO-TECH reported revenue of NTD 303 million in 2022, NTD 625 million in 2023, and NTD 397 million in the first half of 2024. Gross profit for the respective periods was NTD 127 million, NTD 281 million, and NTD 162 million, while pre-tax profit reached NTD 58 million, NTD 185 million, and NTD 104 million.
Basic earnings per share for the same periods were NTD 2.66, NTD 7.66, and NTD 3.24, respectively. Both revenue and profitability demonstrated strong growth.
Source:
China Times Info: https://wantrich.chinatimes.com/news/20240827900515-420101
